iM4TB is a non-profit based in EPFL’s Innovation Park. Founded in 2013, its mission is “to develop better and faster-acting medicines to fight TB and therefore bridge the gap between the scientific discovery and the market in order to provide affordable TB treatment to anyone in the world.” 

iM4TB is chaired by Professor Stewart Cole, a world-renowned TB expert, who also directs EPFL’s Global Health Institute. The non-profit enjoys the patronage of Professor Françoise Barré-Sinoussi, a French virologist who won the Nobel Prize in Medicine (2008) for the discovery of HIV, the virus that causes AIDS. 


EPFL - Innovation Park I

CH-1015 Lausanne, Switzerland


EPFL non-profit iM4TB awarded $2.4m for anti-TB drug clinical trials


Internal Notes: 

EPFL non-profit iM4TB awarded $2.4m for anti-TB drug clinical trials

« The pre-clinical development underpinning PBTZ169 is provided by the Ecole Polytechnique Fédérale de Lausanne (EPFL) and the Bill & Melinda Gates Foundation. PBTZ169 was discovered and developed by the European Commission’s 6th Framework (FP6) consortium NM4TB – New Medicines for Tuberculosis (2006 – 2011) and 7th framework (FP7) consortium MM4TB – More Medicines for Tuberculosis (2011 – 2016). »